Abstract
Moving Targets in Hepatocellular Carcinoma: Hepatic Progenitor Cells as Novel Targets for Tyrosine Kinase Inhibitors
Highlights
It is known that several tumor suppressors or proto-oncogenes are mutated in Hepatocellular carcinoma (HCC), including p53, Rb and IGF. 4 In addition, many intracellular signaling pathways have been shown to contribute to HCC growth
At the 2007 American Society of Clinical Oncology meeting, sorafenib, an oral multikinase inhibitor of raf kinase, VEGFR2, VEGFR3 and PDGFR-β kinases, was reported to lead to an improvement in overall survival by about 3 months when compared with placebo in a large, randomized trial of advanced HCC patients.[6]
Knight and colleagues in this issue of Gastroenterology suggest another possible mechanism of antitumor activity using imatinib for HCC by targeting presumptive hepatic progenitor cells.[15]
Summary
In addition to direct targeting of tumor-related growth pathways, other paradigms for treating cancer have emerged using tyrosine kinase inhibitors. One of these includes targeting the tumor “stroma,” including endothelial cells and fibroblasts which support cancer cell growth.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
